Neumora submits IND for NMRA-215, reports dose data for NMRA-511Nov 16Quarterly updateNeumora Therapeutics, Inc.
Roche posts SKYSCRAPER-01 results for tiragolumab/atezolizumab; registers Phase II Parkinson's trialNov 13Weekly roundup, 9 itemsalectinibastegolimab
Regeneron registry update: new MUC16 trial added; HS, MASH, ALD, melanoma, obesity studies continueNov 12Weekly roundup, 6 itemsALN-CIDEBALN-HSDUpdated
Novo Nordisk registers four Phase 3 AMBITION trials for zenagamtide in type 2 diabetesNov 12Weekly roundup, 5 itemsNovo Nordisk A/SsemaglutideUpdated
iBio reports fiscal Q1 2027 results, advances IBIO-600 and IBIO-610 programsNov 10Clinical readoutiBio, Inc.PMGC Holdings Inc.Updated
Novo Nordisk registers Phase 3 CagriSema hypertension trial; posts results for two other studiesNov 6Weekly roundup, 4 itemsCagrisemaNNC0487-0111Updated
Amgen gets Amjevita label update; registers Phase 3 MariTide trial against semaglutideNov 6Weekly roundup, 5 itemsadalimumab-attoAmgenUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Novo Nordisk: BARI-STEP semaglutide trial results posted; two new Phase 1 studies registeredOct 28Weekly roundup, 7 itemsconcizumabdenecimig
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Dr. Reddy's posts lower revenue and profit for quarter ended September 2026Oct 23PeopleDr Reddys Laboratories Ltd
Lilly posts two DC-806 Phase 1 DDI results; registers three new Phase 3 trialsOct 22Weekly roundup, 11 itemscetuximabdulaglutide
Novo Nordisk registers real-world semaglutide study with Eucalyptus in AustraliaOct 19Trial updateNovo Nordisk A/Ssemaglutide
Novo Nordisk registers two zenagamtide switch studies; IMPLEMENT HF recruitment continuesOct 16Weekly roundup, 3 itemsNovo Nordisk A/SsemaglutideUpdated
Pfizer wins two FDA labeling supplements; obesity trial roster unchangedOct 15Weekly roundup, 8 itemsberobenatidemethotrexate
iBio highlights NHP data showing IBIO-610 may preserve muscle with GLP-1 therapyOct 13Clinical readoutiBio, Inc.
Amgen registers new Phase 3 maridebart cafraglutide vs. semaglutide trial in type 2 diabetesOct 8Weekly roundup, 3 itemsAMG-513AmgenUpdated
Boehringer Ingelheim registers five new trials, spanning oncology, obesity, and ILD screeningOct 2Weekly roundup, 7 itemsBoehringer IngelheimempagliflozinUpdated
Novo Nordisk adds four registrations: new molecule trial, CagriSema switch study, real-world dataOct 2Weekly roundup, 9 itemsCagrisemaNNC0705-0002Updated
Pfizer's Ruxience biosimilar supplement approved; breast cancer trials post resultsSep 30Weekly roundup, 8 itemsatirmociclibberobenatideUpdated
Peking University registers finerenone-semaglutide trial for obesity kidney diseaseSep 30Trial updateBayerfinerenone
Alveus registers Phase 2 trial of ALV-100 for weight-loss maintenance after semaglutideSep 24Trial updateAlveus Therapeutics, Incsemaglutide
Lilly's orforglipron posts Phase 3 diabetes results; six new trials registeredSep 18Weekly roundup, 7 itemsEli Lillyorforglipron
Novo Nordisk registers Phase 3 obesity trial in Japan; new CagriSema switch studySep 16Weekly roundup, 2 itemsCagrisemaNNC0487-0111
iBio reports fiscal 2026 results, cites progress across obesity antibody pipelineAug 28Quarterly updateiBio, Inc.
Novo Nordisk posts PIONEER TEENS results; registers three new trials for obesity and injectionsAug 21Weekly roundup, 4 itemsNNC0721-8060Novo Nordisk A/S
Novo Nordisk posts results for two semaglutide trials, opens new NNC0487-0111 studyAug 14Weekly roundup, 3 itemsNNC0487-0111Novo Nordisk A/S
Veru's Phase 2b PLATEAU trial fully enrolled with 239 obesity patientsAug 10Quarterly updateenobosarmVeru Inc.
Novo Nordisk registers Phase 3 cagrilintide trial; Penn semaglutide study posts resultsAug 4Weekly roundup, 2 itemscagrilintideNovo Nordisk A/S
Novo Nordisk registers Korean MASLD/MASH real-world study and semaglutide back pain trialJul 31Weekly roundup, 2 itemsNovo Nordisk A/Ssemaglutide
Neumora reports favorable NMRA-215 toxicology data, still targets Q4 2026 INDJul 27Clinical readoutNeumora Therapeutics, Inc.
Dr. Reddy's records Rs.2,397 million provision for out-of-spec semaglutideJul 22PeopleDr Reddys Laboratories Ltdsemaglutide